Showing results (101-110 of 195) with videos related to
Sort By:
Pageof 20
British Journal of Cancer|January 1, 1993
2'-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignanciesT Hickish, P Serafinowski, D Cunningham, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1994
High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myelomaD Cunningham, L Paz-Ares, S Milan, et al.Cancer|August 15, 1983
Assessment of response of bone metastases to systemic treatment in patients with breast cancerR C Coombes, P Dady, C Parsons, et al.Cancer Research|September 1, 1986
Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II reportP E Goss, T J Powles, M Dowsett, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1996
The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention studyJ Chang, T J Powles, S E Ashley, et al.British Journal of Cancer|August 1, 1990
Magnetic resonance imaging in the detection of skeletal metastases in patients with breast cancerA L Jones, M P Williams, T J Powles, et al.Breast Cancer Research and Treatment|January 1, 1992
Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatmentP E Lønning, M Dowsett, A Jones, et al.Cancer Research|April 1, 1987
Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and routeM Dowsett, P E Goss, T J Powles, et al.Journal of the National Cancer Institute|May 20, 1998
Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancerT J Powles, E McCloskey, A H Paterson, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2009
The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trialsI Chau, A R Norman, D Cunningham, et al.Pageof 20